Biogen and Bio-Thera Reveal Tocilizumab Progress
Biosimilar Actemra Phase III Results Trigger $30m Payment Under April Deal
Executive Summary
Biogen and Bio-Thera Solutions have reported positive results from a Phase III trial for their BAT1806 proposed biosimilar tocilizumab rival to Actemra. The milestone has triggered a $30m payment from Biogen under the pair’s development deal.
You may also be interested in...
Biogen’s RoActemra Biosimilar Begins EU Approvals Process
The European Medicines Agency has accepted Biogen’s marketing authorization submission for its BIIB800, developed by Chinese firm Bio-Thera.
Biogen and Bio-Thera Report Progress On Tocilizumab
Biogen and Bio-Thera have revealed positive Phase III data for their proposed tocilizumab biosimilar rival to Actemra/RoAcetmra.
Bio-Thera Follows Hikma Deal With Sandoz Bevacizumab Alliance
Sandoz has plugged another gap in its off-patent oncology pipeline, from which the company has rolled-out four marketed oncology biosimilars, by bringing in Bio-Thera Solutions’ BAT1706 proposed biosimilar to Avastin, including in the US and Europe.